Skip to content
Menu

Pyxis Oncology, Inc. PYXS

Full chart Compare
Set alert

Price alert · PYXS

All alert types
1.58 USD 0.00 (+0.00%)

Regular-session close

1.66 +0.08 +5.06%

Pre-market · Nov 16, 7:22 AM ET

1.52 Day range 1.60
1.03 52-week range 5.55
YTD
+37.39%
1 year
-64.73%

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 10.00 +532.9% upside
Target (low)
5.00
Target (mean)
10.00
Target (high)
13.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 8
  • 1 month ago 8
  • 2 months ago 7
  • 3 months ago 7

Revenue and earnings: history and forecast

What PYXS reported, and what analysts expect for the next two fiscal years

Earnings per share

Analysts expect earnings per share of -1.00 in the current fiscal year.

Fiscal years. Estimates are the analyst consensus and change as analysts revise them; the percentages are the change on the year before. Earnings per share is on the basis analysts estimate, which can differ from the reported (GAAP) figure.

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PYXS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.28571-0.37 – -0.23-0.33+13.4%00.0%7
Next quarter-0.33-0.38 – -0.29-0.06-450.0%0-100.0%3
Current year-1.00-1.29 – -0.88-1.85+45.8%13.80M0.0%7
Next year-1.19-1.35 – -0.98-1.00-18.8%0-100.0%7

Upgrades and downgrades

The latest rating changes

PYXS analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 20, 2024RBC CapitalReiteratedOutperformOutperform
Nov 21, 2024RBC CapitalMaintainedOutperformOutperform
Nov 21, 2024William BlairDowngradeOutperformMarket Perform
Nov 21, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 8, 2024Stephens & Co.Initiated—Overweight
Sep 19, 2024RBC CapitalReiteratedOutperformOutperform
Aug 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 8, 2024StifelInitiated—Buy
May 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Apr 10, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 22, 2024RBC CapitalReiteratedOutperformOutperform
Mar 22, 2024HC Wainwright & Co.MaintainedBuyBuy
Feb 9, 2024BTIGInitiated—Buy
Jan 23, 2024Leerink PartnersInitiated—Outperform
Nov 30, 2023HC Wainwright & Co.Initiated—Buy
Sep 5, 2023RBC CapitalInitiated—Outperform
Jul 31, 2023EF HuttonInitiated—Buy
Mar 23, 2023Credit SuisseReiterated—Outperform
Nov 2, 2021B of A SecuritiesInitiated—Neutral
Nov 2, 2021JefferiesInitiated—Buy
Nov 2, 2021Credit SuisseInitiated—Outperform

Included in Plus and up

Sign in to see Analyst trend

Two years of the analyst rating mix and the average price target against the price.